PharmAthene, Inc. (AMEX:PIP)
About PharmAthene, Inc. (AMEX:PIP) PharmAthene, Inc. is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. It has five product candidates in various stages of development: SparVax, recombinant protective antigen (rPA) anthrax vaccine; Valortim, a human monoclonal antibody for the prevention and treatment of anthrax infection; Protexia, a recombinant enzyme (butyrylcholinesterase), which mimics a natural bioscavenger for the prevention or treatment of nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides; a third generation rPA anthrax vaccine, and RypVax, a recombinant dual antigen vaccine for pneumonic and bubonic plague (rYP).